Plasma Exchange and Its Development in the Treatment of Familial Hypercholesterolemia

  • M. Mancini
  • A. Postiglione
  • A. Gnasso

Abstract

The treatment of patients with homozygous familial hypercholesterolemia (FH) is a difficult and daunting clinical problem. Diet and drugs have little influence on the hypercholesterolemia of these patients; combinations of cholestyramine and nicotinic acid [1], compactin [2] and probucol [3] have also been tried but all have failed to provide adequate and satisfactory control of the disease. More recently mevinolin, a specific HMG-CoA reductase inhibitor, has produced good results in the treatment of heterozygous FH [4], but data on the homozygous form are still lacking.

Keywords

Cholesterol Cellulose Heparin Thrombin Dextran 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moutafis CD, Myant NB, Mancini M, Oriente P (1971) Cholestyramine and nicotinic acid in the treatment of familial hyperbetalipoproteinemia in homozygous form. Atherosclerosis 14: 247PubMedCrossRefGoogle Scholar
  2. 2.
    Yamamoto A, Sudo H, Endo A (1980) Therapeutic effects of ML–236 B in primary hypercholesterolemia. Atherosclerosis 35: 259PubMedCrossRefGoogle Scholar
  3. 3.
    Baker SG, Joffe BI, Mendelsohn D, Seftel MC (1982) Treatment of homozygous familial hypercholesterolemia with probucol. S Afr Med J 62: 7PubMedGoogle Scholar
  4. 4.
    Grundy SM, Bilheimer DW (1984) Influence of inhibition of 3-hydroxy–3-methylglutaryl CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effect on cholesterol balance. Proc Natl Acad Sci USA 81: 2538PubMedCrossRefGoogle Scholar
  5. 5.
    Miettinen TA (1980) Comparison of cholestyramine, ileal by-pass and portacaval shunt in the treatment of familial hypercholesterolemia. In: Gotto AM, Smith LC, Allen B (eds) Atherosclerosis V. Springer, Berlin Heidelberg New York, p 470Google Scholar
  6. 6.
    Stein EA, Glueck CJ (1980) Homozygous familial hypercholesterolemia, treatment of portacaval shunt. In: Gotto AM, Smith LC, Allen B (eds) Atherosclerosis V. Springer, Berlin Heidelberg New York, p 474Google Scholar
  7. 7.
    Forman MB, Baker GG, Mieny CJ, Joffe B, Sandler MP, Mendelsohn D, Seftel HC (1982) Treatment of homozygous familial hypercholesterolemia with portacaval shunt. Atherosclerosis 41: 349PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange in the management of familial hypercholesterolemia. Lancet 1: 1208PubMedCrossRefGoogle Scholar
  9. 9.
    Witztum JL, William JC, Ostlund R, Sherman L, Siccard G, Schonfeld G (1980) Successful plasmapheresis in a four year old child with homozygous familial hypercholesterolemia. J Pediatr 97: 615PubMedCrossRefGoogle Scholar
  10. 10.
    Thompson GR (1979) Management of familial hypercholesterolemia and new approaches to the treatment of atherosclerosis. In: Paoletti R, Gotto AM (eds) Atherosclerosis Review, vol 5. Raven, New York, p 67Google Scholar
  11. 11.
    Thompson GR (1981) Plasma exchange for hypercholesterolemia. Lancet 1: 1246PubMedCrossRefGoogle Scholar
  12. 12.
    Thompson GR (1981) Long-term plasma exchange in severe familial hypercholesterolemia. In: NIH (ed) Proceedings of the workshop on therapeutic plasma pheresis. NIH, Washington, p 1665Google Scholar
  13. 13.
    Thompson GR (1983) Plasma exchange and affinity chromatographic therapy for hyperlipoproteinemia: a review. Apheresis Bull 1: 26Google Scholar
  14. 14.
    Keller C, Hailer S, Demant T, Wolfram G, Zöllner N (1985) Effect of plasma exchange with and without concomitant drug treatment on lipids and lipoproteins in patients with familial hypercholesterolemia confirmed by tissue culture. Atherosclerosis 57: 225PubMedCrossRefGoogle Scholar
  15. 15.
    Kilpatrick D, Fleming J, Clyne C, Thompson GR (1979) Reduction of blood viscosity following plasma exchange. Atherosclerosis 32: 301PubMedCrossRefGoogle Scholar
  16. 16.
    Postiglione A, Soricelli A, Lamenza F, Scarpato N, Montefusco S (1982) Plasma exchange for the treatment of cerebrovascular disease in familial hypercholesterolemia. J Chronic Dis Ther Res 6: 213Google Scholar
  17. 17.
    Rubba P, Postiglione A, Scarpato N, Iannuzzi A, Mancini M (1985) Improved reactive hyperemia test after plasma exchange in familial hypercholesterolemia. Atherosclerosis 56: 237PubMedCrossRefGoogle Scholar
  18. 18.
    Di MinnoG, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M (1986) Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis 6: 203CrossRefGoogle Scholar
  19. 19.
    Brook GI, Winterstein G, Aviram M (1983) Platelet function and lipoprotein levels after plasma exchange in patients with familial hypercholesterolemia. Clin Sci 64: 637PubMedGoogle Scholar
  20. 20.
    Weber G, Bianciardi G, Toti P, Scarpato N, Postiglione A, Mancini M (1984) Ultrastructural features of circulating platelets from hypercholesterolemic (type II a) patients submitted to plasma exchange. A freeze etching study. In: Carlson LA, Olsson AG (eds) Treatment of hyperlipoproteinemia. Raven, New York, p 143Google Scholar
  21. 21.
    Lupien PJ, Moorjani S, Awad J (1976) A new approach to the management of familial hyper-cholesterolemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet 1: 1261PubMedCrossRefGoogle Scholar
  22. 22.
    Lupien PJ, Moorjani S, Gagne C, Brun LD, Lou M, Dagenais G (1982) Long term treatment of two familial hypercholesterolemic heterozygote patients with batch affinity chromatography ( BAC ). Artery 10: 288Google Scholar
  23. 23.
    Stoffel W, Demant T (1981) Selective removal of apolipoprotein B-containing lipoproteins from blood plasma. Proc Natl Acad Sei USA 78: 611CrossRefGoogle Scholar
  24. 24.
    Stoffel W, Borberg H, Greve V (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hyperlipoproteinemia. Lancet 2: 1005PubMedCrossRefGoogle Scholar
  25. 25.
    Stoffel W, Bode C (1984) Selective removal of low density lipoproteins. In: Pineda AA (ed) Selective plasma component removal. Mount Kisco, New York, p 1Google Scholar
  26. 26.
    Tauchert M, Stoffel W, Bode C (1982) LDL-apheresis in patients with hypercholesterolemia type IIa (Abstr). Circulation 68: 111–290Google Scholar
  27. 27.
    Fuchs C, Windisch M, Wieland H (1983) Selective continuous extracorporeal elimination of low density lipoproteins from plasma by precipitation with heparin without cations ( Abstr ). Proc Annu Meet Am Soc Artif Intern Organs 12: 82Google Scholar
  28. 28.
    Yokoyama S, Kikkawa T, Hayashi R (1983) Plasmapheresis therapy of hypercholesterolemias. In: Nose Y, Malchesky PS, Smith JW (eds) Plasmapheresis: New trends in therapeutic applications. ISAO, Cleveland, p 231Google Scholar
  29. 29.
    Yokoyama S, Hayashi R, Kikkawa T (1984) Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis: characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis 4: 276PubMedCrossRefGoogle Scholar
  30. 30.
    Sakai K, Mabuchi H (1985) Plasma exchange therapy for homozygous familial hypercholesterolemia with a dextran sulfuric acid cellulose column (KNA-01). 17th General Assembly of the Japan Society of the Study of Arteriosclerosis, SendaiGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • M. Mancini
  • A. Postiglione
  • A. Gnasso

There are no affiliations available

Personalised recommendations